Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5782)
All Articles published online
|
Publishing Process of This Article
|
Sep 19, 2021 (publication date) through Mar 26, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Soyka M, Franke AG. Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations. World J Psychiatr 2021; 11(9): 543-552 [PMID: 34631459 DOI: 10.5498/wjp.v11.i9.543] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v11/i9/543.htm |
| Number | Citing Articles |
| 1 |
Catharine Montgomery, Yasir Abbasi, Devon De Silva, Rosalind Gittins, Andrew Jones, Marie-Claire Van Hout. Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder. BMJ Open 2025; 15(2): e090736 doi: 10.1136/bmjopen-2024-090736
|
| 2 |
Victoria E. Stead, Andrew B. Lumb, Jennifer Brasch, James MacKillop. Science-Based Therapy. 2025; : 193 doi: 10.1017/9781009086264.013
|
| 3 |
Raul Felipe Palma-Alvarez, Germán Ortega-Hernández, Maria Roch-Santed, Josep Antoni Ramos-Quiroga, Lara Grau-López. Long-acting injectable buprenorphine in the real world: case report on dual disorders. Journal of Addictive Diseases 2024; : 1 doi: 10.1080/10550887.2024.2354566
|
| 4 |
Phyo Aung, Margaret Hellard, Paul Dietze, Bek Petrovic, Peter Higgs, Mark Stoové. Practical solutions to resolve social barriers to hepatitis C treatment initiation among people who inject drugs: a qualitative study. Harm Reduction Journal 2024; 21(1) doi: 10.1186/s12954-024-01136-1
|
| 5 |
Pouya Azar, Jane J. Kim, Ella Rohani, Dayyon Newman-Azar, Matin Narimani, Jessica Machado, Victor W. Li. Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy. Frontiers in Psychiatry 2025; 16 doi: 10.3389/fpsyt.2025.1500799
|
| 6 |
Stephen Parkin, Joanne Neale, John Strang. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder. Substance Use & Misuse 2023; 58(13): 1696 doi: 10.1080/10826084.2023.2244064
|
| 7 |
Hannah A. Blair. Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA. Drugs & Therapy Perspectives 2024; 40(2): 61 doi: 10.1007/s40267-024-01055-y
|
| 8 |
Tanja Schwarz, Judith Anzenberger, Martin Busch, Gerhard Gmel, Ludwig Kraus, Michael Krausz, Florian Labhart, Maximilian Meyer, Michael P. Schaub, Jean N. Westenberg, Alfred Uhl. Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and Switzerland. Drug and Alcohol Dependence 2024; 254: 111036 doi: 10.1016/j.drugalcdep.2023.111036
|
| 9 |
Andrew Burton, Darlene J. DeBona, Michele Handzel, Sarah Kelly-Pisciotti, Min Qiao, Dana Rojek, Nicole M. Acquisto. Surgical removal of extended-release buprenorphine depot due to adverse reactions. The American Journal of Emergency Medicine 2024; 81: 127 doi: 10.1016/j.ajem.2024.04.047
|
| 10 |
Cayley Russell, Tony P. George, Nitin Chopra, Bernard Le Foll, Flora I. Matheson, Jürgen Rehm, Shannon Lange. Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review. The American Journal of Drug and Alcohol Abuse 2024; 50(5): 567 doi: 10.1080/00952990.2024.2360984
|